Northridge, CA and Cambridge, UK, 21 November 2014- Avita Medical Ltd. (ASX:AVH), (OTCQX:AVMXY) a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today released CEO's Annual General Meeting Company Presentation. To view or download:AGM Presentation.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray‐On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Contact:
Clare Matschullat
Blueprint Life Science Group
Phone:+1 415-375-3340 x106
Email:cmatschullat@pblifescience.com

Regards,

Avita Medical
9221 Corbin Avenue, Suite 220
Northridge, CA 91324
T: +1 818 356 9400 F: +1 818 356 9416
Email:investor@avitamedical.com
Web:www.avitamedical.com

distributed by